Nike Isn't Afraid of Competition in the Sneaker Wars
Nike hopes its newest running shoe will help athletes improve their performance, and the company’s vice president of running footwear credits the way the sneaker is manufactured with helping achieve that goal.
“We use computational design, which is informing this pattern that you see on the midsole and outsole, so that’s called our fluid geometry” said Brett Holts in an interview with Cheddar. “What this allows us to do is iterate much quicker.”
“We can take thousands of data inputs from elite athletes, every day runners, our research lab. We can put all those inputs into a computer program, and it spits out an algorithm that gives us this fluid geometry.”
But the competition is heating up. Last year Adidas, which touts its own BOOST technology, overtook Nike’s Michael Jordan-fronted line as the #2 brand in U.S. sports footwear.
Holts, though, isn’t intimidated.
“We feel like [competition] continues to push us, continues to keep us sharp,” he said.
The Nike Epic React Flyknit will be available on February 22 and cost $150.
For full interview [click here](https://cheddar.com/videos/inside-nikes-newest-innovation).
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
